Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ELANE | P08246 | 1/20 | 0.46 |
| ▸ | CD69 | Q07108 | 1/20 | 0.46 |
| ▸ | TLR4 | O00206 | 4/20 | 0.43 |
| ▸ | CD14 | P08571 | 4/20 | 0.43 |
| ▸ | LY96 | Q9Y6Y9 | 4/20 | 0.43 |
| ▸ | PTPRC | P08575 | 4/20 | 0.41 |
| ▸ | PTPN2 | P17706 | 4/20 | 0.41 |
| ▸ | PTPN1 | P18031 | 4/20 | 0.41 |
| ▸ | PTPRB | P23467 | 4/20 | 0.41 |
| ▸ | PTPN11 | Q06124 | 4/20 | 0.41 |
| ▸ | GSTA1 | P08263 | 4/20 | 0.36 |
| ▸ | GSTP1 | P09211 | 4/20 | 0.36 |
| ▸ | RARG | P13631 | 1/20 | 0.31 |
| ▸ | RXRA | P19793 | 1/20 | 0.31 |
| ▸ | PPARG | P37231 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14617495 | 0.84 | ELANE (0.45) | ELANECD69TLR4CD14LY96 | |
| SCHEMBL17030888 | 0.83 | TLR4 (0.36) | ELANECD69TLR4CD14LY96 | |
| SCHEMBL13987040 | 0.82 | ELANE (0.58) | ELANECD69TLR4CD14LY96 | |
| SCHEMBL17030882 | 0.78 | ELANE (0.30) | ELANECD69 | |
| SCHEMBL14617493 | 0.77 | ELANE (0.53) | ELANECD69TLR4CD14LY96 | |
| SCHEMBL14617494 | 0.76 | PTPRC (0.57) | ELANECD69TLR4CD14LY96 | |
| SCHEMBL16545626 | 0.74 | CD69 (0.83) | ELANECD69TLR4CD14LY96 | |
| SCHEMBL16545623 | 0.71 | CD69 (0.65) | ELANECD69TLR4CD14LY96 | |
| SCHEMBL9134209 | 0.70 | TLR4 (0.41) | ELANECD69TLR4CD14LY96 | |
| SCHEMBL14617487 | 0.70 | ELANE (0.46) | ELANECD69TLR4CD14LY96 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8969607-B2 | Calixarene-bound iridium-containing metal colloids | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2015-03-03 | — | — | US | disclosed |
| US-20130018199-A1 | CALIXARENE-BOUND IRIDIUM-CONTAINING METAL COLLOIDS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2013-01-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130018199-A1 | CALIXARENE-BOUND IRIDIUM-CONTAINING METAL COLLOIDS | CALR, CALD1, CALU | ELANE 482/4885CD69 2506/4885TLR4 4627/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.